Enlivex Therapeutics

NAQ:ENLV · IL0011319527

BiotechnologyX-Small

360° View

Value81

Price/Sales—

Price/Earnings84

Price/Book72

Dividend Yield1

Growth20

Revenue Growth—

Profit Growth58

Capital Growth17

TSR 52w17

Safety100

Leverage95

Liquidity85

Refinancing100

Combined91

Sentiment23

Analyst Opinions100

Pro Holdings9

Opinion Changes50

Market Pulse17

Profile

CountryIsrael

IndustryBiotechnology

SizeX-Small

TypePublic Company

ExchangeNASDAQCM

Employees37

Websiteenlivex.com

ISINIL0011319527

Last UpdateApr 2, 2026

Index & Theme

ImmunologyStem Cell TherapyInflammationOncologyRheumatologyOrthopaedicsHealth CareInformation TechnologyTherapeutics

Description

Enlivex Ltd. focuses on advancing therapies designed to extend health span and improve quality of life, powered by a prediction markets treasury. The company operates a dual strategy that combines clinical development in quality longevity therapeuti…

Analysis

Enlivex Therapeutics's 360° View rank of 68 places it above its peer average — better than 68% of its true peers.

It's lagging on growth (20) and looks cheap versus peers (81). On safety it is very well financed (100), and the market shows skeptical sentiment (23). Taken together, its Combined rank of 91 reads as among the strongest overall.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Enlivex Therapeutics with its peers

Galapagos

AEX:GLPG

CountryBelgium

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

MindMaze Therapeutics Holding

SWX:MMTX

CountrySwitzerland

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Kiniksa Pharmaceuticals

NSQ:KNSA

CountryUK

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Tiziana Life Sciences

NAQ:TLSA

CountryUK

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Oxford Biomedica

LSE:OXB

CountryUK

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

BeOne Medicines

SHH:688235

CountrySwitzerland

IndustryBiotechnology

SizeX-Large

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →